EVALUATION OF THE EFFECT OF THE OPHTHALMIC REMEDIES COMBINATION ON THE VIABILITY OF HUMAN CONJUNCTIVAL CELL CULTURE CHANG CONJUNCTIVA

Objective. Investigation of the cytological and immunological effects, caused by the simultaneous exposure of normal Chanq conjunctiva cells to ophthalmic drugs Broxinac® and Ophthalmoferon®, in order to improve the evaluation techniques of ophthalmic drugs combinations in vitro.

Material and methods. A transplantable culture of normal Chang conjunctiva cells, clone 1-5 C-4, was used. The drugs Broksinak® and Oftalmoferon® were quantified by their effect on cell viability using the MTT method. The change in cell morphology during the cultivation process was studied by intravital visual observation. The effect of the combination of drugs on the functional activity of conjunctival cells was assessed by production of cytokines at the level of their in vitro transcription.

Results. The investigated drugs (dilutions 1/512-1/2048 Broksinak® and 1/32-1/2048 Oftalmoferon®) were incubated with human Chang conjunctiva cells for 48 hours and did not cause an inhibition of growth activity or viability, and did not change the morphology of the cells, and the test sample was not different from the state of the control cells. Cytokine production by cells of the conjunctiva when exposed to Broksinak® alone stimulated secretion of antiviral IFN-α and IFN-λ and inhibition of production of proinflammatory IFN-γ, IL-2, IL-8, IL-12. Ophthalmoferon stimulated the production of IFN-α and VEGF R1. The production of RNA IFN-α, IFN-λ2, IL-2, IL-12 was observed in drug’s combination.

Сonclusions. The combined use of Broksinak® and Oftalmoferon® on human Chang conjunctiva cells results in the formation of an adequate antiviral and anti-inflammatory cytokine response: i.e. increase of IFNalpha production, IFN-lambda, IL-2 and IL-12.

1. Yawata N, Selva KJ, Liu YC, Tan KP, Lee AW, Siak J, Lan W, Vania M, Arundhati A, Tong L, Li J, Mehta JS, Yawata M. Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal immunology. 2016;9(1):159-170. DOI: 10.1038/mi.2015.47.

2. Diebold Y, Calonge M, Enriquez de Salamanca A., Callejo S, Corrales RM, Saez V, Siemasko KF, Stern ME. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Investigative ophthalmology and visual science. 2003;44(10):4263–4274.

3. Ammar DA.,Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Journal Molecular Vision.2011;17:1806-1813.

4. Schuerer N, Stein E, Inic-Kanada A, Pucher M, Hohenadl C, Bintner N, Ghasemian E, Montanaro J, Barisani-Asenbauer T. Implications for Ophthalmic Formulations: Ocular Buffers Show Varied Cytotoxic Impact on Human Corneal-Limbal and Human Conjunctival Epithelial Cells. Cornea. 2017;36(6):712-718. DOI: 10.1097/ICO.0000000000001199.

5. Ayaki M, Iwasawa A, Soda M, Yaguchi S, Koide R. Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines. Clinical ophthalmology (Auckland, N.Z.). 2010;4:1019-1024.

6. Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clinical and experimental ophthalmology. 2008;36(6):553-559. DOI: 10.1111/j.1442-9071.2008.01803.x

7. Sawazaki R, Ishihara T, Usui S, Hayashi E, Tahara K, Hoshino T, Higuchi A, Nakamura S, Tsubota K, Mizushima T. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. Investigative ophthalmology and visual science. 2014;55(4):2547-2556. DOI: 10.1167/iovs.13-13850.

8. Qu M, Wang Y, Yang L, Zhou Q Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components. Molecular vision. 2011;17:3147-3155.

9. Kinnunen K, Kauppinen A, Piippo N, Koistinen A, Toropainen E, Kaarniranta K Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures. Experimental eye research. 2014;120:82-89. DOI: 10.1016/j.exer.2014.01.006.

10. Александрова О.И., Околов И.Н., Тахтаев Ю.В., Хорольская Ю.И., Хинтуба Т.С., Блинова М.И. Сравнительная оценка цитотоксичности антимикробных глазных капель. Офтальмологические ведомости. 2015;8(1):8997. [Aleksandrova OI, Okolov IN, Takhtaev YuV, Khorol’skaya YuI, Khintuba TS, Blinova MI. A comparative evaluation of antimicrobial eye drops cytotoxicity. Ophthalmology journal=Oftal’mologicheskie vedomosti.2015;8(1):89-97. (in Russ)].

11. Александрова О. И., Хорольская Ю. И., Майчук Д. Ю., Блинова М. И. Исследование общей цитотоксичности антибиотиков аминогликозидного и фторхинолонового ряда на клеточных культурах. Вестник Офтальмологии. 2015;131(5):43-53.[ Aleksandrova OI, Khorol’skaya YuI, Maychuk DYu, Blinova MI. Study of common cytotoxicity of aminoglycoside and fluoroquinolone antibiotics in cell cultures. Annals of Ophthalmology=Vestnik oftal’mologii. 2015;131(5):4353(in Russ)].

12. Акберова С.И., Ершов Ф.И., Мусаев Галбинур П.И. Динамика интерферонового статуса у больных с герпетическими кератитами при лечении новым индуктором интерферона актиполом. Вестник офтальмологии. 2001;117(1):3335. [Akberova SI, Ershov FI, Musaev Galbinur PI. Dynamics of interferon status in patients with herpetic keratitis in the treatment of a new interferon inducer actipol. Annals of Ophthalmology=Vestnik oftal’mologii. 2001;117(1):33-35. (in Russ)].

13. Кочергин С.А., Чернакова Г.М., Клещева Е.А., Шаповал И.М., Мезенцева М.В. Локальный цитокиновый статус при хронических формах аденовирусной инфекции глаз. Вестник Российской академии естественных наук. 2012;1:61-67. [Kochergin SA, Chernakova GM, Kleshcheva EA, Shapoval IM, Mezentseva MV. Local cytokine status of the chronic forms of adenoviral eye infection. Bulletin of the Russian Academy of Natural Science=Vestnik Rossiiskoi akademii estestvennykh nauk. 2012;1:61-67. (in Russ)].

14. Майчук Д.Ю., Васильева О.А., Руссу Л.И., Мезенцева М.В. Сравнительная клинико-иммунологическая оценка вариантов терапии инфильтративного поражения роговицы после перенесенного аденовирусного кератоконъюнктивита. Вестник офтальмологии. 2015;131(4): 49-55. [Maychuk DYu, Vasil’eva OA, Russu LI, Mezentseva MV. Clinical and immunological comparisons of therapeutic regimens for corneal infiltrates secondary to adenoviral keratoconjunctivitis. Annals of Ophthalmology=Vestnik oftal’mologii.2015;131(4): 49-55. (in Russ)].

15. Lin Y, Zhang M, Barnes PF. Chemokine production by human alveolar epithelial cell line in response by Mycobacterium tuberculosis. Infection and Immunity. 1998;66(3):1121-1126. DOI: 10.1128/IAI.70.2.577-583.2002

16. Leonardi A, DeFranchis G, Fregona IA, Violato D, Plebani M, Secchi AG. Effects of cyclosporin A on human conjunctival fibroblasts. Archives of ophthalmology. 2001;119(10):1512-1517.

17. Li J, Lehmann C, Chen X, Romerio F, Lu W. Total chemical synthesis of human interferon alpha-2b via native chemical ligation. Journal of peptide science. 2015;21(7):554-560. DOI: 10.1002/psc.2760.

18. Contreras-Ruiz L, Schulze U, García-Posadas L, Arranz-Valsero I, Lopez-García A, Paulsen F, Diebold Y. Structural and functional alteration of corneal epithelial barrier under inflammatory conditions. Current eye research. 2012;37(11):971-981. DOI: 10.3109/02713683.2012.700756.

19. Lambiase A, Micera A, Bonini S Multiple action agents and the eye: do they really stabilize mast cells? Current opinion in allergy and clinical immunology. 2009;9(5):454-465. DOI: 10.1097/ACI.0b013e3283303ebb.

20. Guzman-Aranguez A, Calvo P, Ropero I, Pintor J. In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells. Journal of ocular pharmacology and therapeutics. 2014;30(9):790-798. DOI: 10.1089/jop.2014.0030.

21. Choi WS, Koh JW, Chung TY, Hyon JY, Wee WR, Shin YJ Cytotoxicity of ganciclovir on cultured human corneal endothelial cells. Antiviral therapy. 2013;18(6):813-820. DOI: 10.3851/IMP2556.

22. Майчук, Ю. Ф. Фармакотерапия аллергических заболеваний глаз. М., 1997. [Maychuk, YuF. Pharmacotherapy of allergic eye diseases. Moscow, 1997. (in Russ)].

23. Сычев Д.А., Отделенов В.А., Андреев Д.А., Богова О.Т., Бордовский С.П., Салпагарова З.К., Головина О.В., Данилина К.С., Захарова Г.Ю., Ильина Е.С., Клейменова Е.Б., Краснова Н.М., Назаренко Г.И., Орехов Р.Е., Пающик С.А., Сосновский Е.Е., Шуев Г.Н., Яшина Л.П. Полипрагмазия в клинической практике: проблема и решения. Санкт-Петербург: ЦОП «Профессия»; 2016. [Sychev DA, Otdelenov VA, Andreev DA, Bogova OT, Bordovskiy SP, Salpagarova ZK, Golovina OV, Danilina KS, Zakharova GYu, Il’ina ES, Kleymenova EB, Krasnova NM, Nazarenko GI, Orekhov RE, Payushchik SA, Sosnovskiy EE, Shuev GN, Yashina LP. Polypharmacy in clinical practice: problem and solutions. St.petersburg: TsOP «Professiya»; 2016. (in Russ)].

24. Сычев Д.А. Как избежать «фармагеддона». электронный ресурс http://gmpnews.ru/2015/07/dmitrij-sychev-kak-izbezhat-farmageddona/. Ссылка активна на 17.10.2017. [Sychev DA. How to avoid “Farmageddon”. electronic resource http://gmpnews.ru/2015/07/dmitrij-sychev-kak-izbezhat-farmageddona/.Link is active on 05.06.2017. (in Russ)].

25. Хабриев Р.У. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М.: Медицина; 2005. [Khabriev RU. Manual on experimental (preclinical) study of new pharmacological substances. Moscow, Meditsina; 2005. (in Russ)].